Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel that could help them be successful in their quest.Translate Bio Inc (NASDAQ: TBIO) rallied strongly earlier in the week on the back of news concerning an expansion of its vaccine development partnership with Sanofi SA (NASDAQ: SNY) but eventually gave back some of the gains following a secondary offering. Vaxart Inc (NASDAQ: VXRT), another COVID-19 vaccine play, rallied during the week.View more earnings on IBBThe FDA review machinery worked overtime, ruling on a host of investigational therapies. Three biopharma companies went public this week, raising a combined $485 million in gross proceeds.The following are key catalysts in the unfolding week:Conferences * Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19: Tuesday, June 30Clinical Readouts/Presentations Q2 Releases * Intra-Cellular Therapies Inc (NASDAQ: ITCI) is scheduled to release top-line results from Phase 1/2 clinical trial of ITI-214, its phosphodiesterase 1 inhibitor, in patients with chronic systolic heart failure. * Obseva SA (NASDAQ: OBSV) will release Phase 3 PRIMROSE 1, 6-month primary endpoint results and PRIMROSE 2 twelve-month data for Linzagolix in uterine fibroids. * Novavax, Inc. (NASDAQ: NVAX) is scheduled to release top-line data from Matrix M vaccine adjuvant, which is a key component of Serum Institute of India's malaria vaccine candidate. * Revance Therapeutics Inc (NASDAQ: RVNC) is due to release Phase 2 top-line data for DAXI in forehead lines and crow's feet. * Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) is expected to release topline data from the pivotal CONNECT-FX trial that is evaluating Zygel in Fragile X syndrome. * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) will release interim results from Phase 2 studies of ALXN2040 in C3 Glomerulopathy. * Iterum Therapeutics PLC (NASDAQ: ITRM) is due to release Phase 3 topline results from sulopenem clinical trials in uncomplicated urinary tract infections.See also: Novavax Gains Over 50% In June: What's Driving The Rally? First-Half Releases * Cerecor Inc (NASDAQ: CERC) is due to release initial data readout from the Phase 1 trial of CERC-802 in healthy volunteers. * Novartis AG (NYSE: NVS) will release Phase 2 data for LJN452 in non-alcoholic steatohepatitis. * Regenxbio Inc (NASDAQ: RGNX) is due to give a program update from the Phase 1/2 trial of RGX-501 for the treatment of Homozygous Familial Hypercholesterolemia. * BioNTech SE - ADR (NASDAQ: BNTX) will release Phase 1 data for BNT111 in advanced melanoma.June Releases * Inovio Pharmaceuticals Inc (NASDAQ: INO) will release interim Phase 1 data for its coronavirus vaccine candidate INO-4800.Earnings * Avid Bioservices Inc (NASDAQ: CDMO) (Tuesday after the close) IPO Quiet Period Expiration * Pliant Therapeutics Inc (NASDAQ: PLRX) * Legend Biotech Corp (NASDAQ: LEGN) * Applied Molecular Transport Inc. (NASDAQ: AMTI) * CALLIDITAS THER/S ADR (NASDAQ: CALT) * Related Link: The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts See more from Benzinga * The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy * The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
No comments:
Post a Comment